StockData
Eikon Therapeutics, Inc. logo

Eikon Therapeutics, Inc. (EIKN) stock

EIKNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$5.17+0.02 (+0.39%)

Close on Nov 18, 2026Market cap $280.03MP/E –Yield –

Eikon Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$93.39M–
Q1 FY2026Mar 31, 2026-$87.34M–
Q2 FY2025Jun 30, 2025-$109.64M–
Q1 FY2025Mar 31, 2025-$71.38M–

More Eikon Therapeutics figures

See a number that looks wrong?